CMAJ • September 26, 2006; 175 (7). doi:10.1503/cmaj.060284.
© 2006 CMA Media Inc. or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
This Article
Right arrow Abstract
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dial, S.
Right arrow Articles by Suissa, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dial, S.
Right arrow Articles by Suissa, S.
Related Collections
Right arrow Drugs: gastrointestinal system
Right arrow Clostridium difficile
Right arrowRelated Article

Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy

Sandra Dial, J.A. Chris Delaney, Verena Schneider and Samy Suissa

From the Division of Clinical Epidemiology, Royal Victoria Hospital, McGill University Health Centre, and the Department of Epidemiology and Biostatistics, McGill University, Montréal, Que. (all authors)


View this table:

[in a new window]
  		Table 1.

 

View this table:

[in a new window]
  		Table 2.